Investing.com - Financial Markets Worldwide

SinoMab BioScience Ltd (3681)

Hong Kong
Currency in HKD
3.05
+0.16(+5.54%)
Closed·
3681 Scorecard
Full Analysis
Analysts anticipate sales growth in the current year
3681 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
2.893.12
52 wk Range
0.803.76
Key Statistics
Edit
Bid/Ask
3.05 / 3.05
Prev. Close
3.05
Open
2.89
Day's Range
2.89-3.12
52 wk Range
0.8-3.76
Volume
8.83M
Average Volume (3m)
17.25M
1-Year Change
80.63%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
3681 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 11
Stock has taken a big hit over the last week
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

SinoMab BioScience Ltd Company Profile

SinoMab BioScience Limited, a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of therapeutics for the treatment of immunological diseases primarily monoclonal antibody (mAb)-based biologics in Mainland China and Hong Kong. Its product pipeline comprises SM03 (Suciraslimab), a first-in-target anti-CD22 mAb, which is in Phase III clinical trial for the treatment of rheumatoid arthritis (RA); is in phase II clinical trial to treat non-Hodgkin’s lymphoma and systemic lupus erythematosus; and is in phase I clinical trial to treat alzheimer’s disease and sjogren’s syndrome. It also develops SM17, a humanized anti-IL-25 receptor, which is in phase I clinical trial to treat asthma and atopic dermatitis, as well as in preclinical trial to treat idiopathic pulmonary fibrosis; and SN1011, a Bruton’s tyrosine kinase inhibitor, which is in Phase II clinical trial for the treatment of pemphigus, neuromyelitis optica spectrum disorder, and multiple sclerosis, as well as in phase 1 clinical trial to treat systemic lupus erythematosus. In addition, the company is developing SM06, a humanised Anti-CD22, that is in preclinical trial to treat systemic lupus erythematosus, rheumatoid arthritis, neuromyelitis optica spectrum disorder, and sjogren’s syndrome; and SM09, a humanised Anti-CD22, which is in preclinical trial to treat non-hodgkin’s lymphoma and autoimmune diseases. Further, it develops Anti-CGC antibody, which is in preclinical trial to treat vitiligo and alopecia areata; and Bispecific antibody candidate (bsAb), which is in preclinical trial to treat osteoporosis. SinoMab BioScience Limited was incorporated in 2001 and is headquartered in Tai Po, Hong Kong.

Industry
Pharmaceuticals
Sector
Healthcare
Employees
95
Market
Hong Kong

Compare 3681 to Peers and Sector

Metrics to compare
3681
Peers
Sector
Relationship
P/E Ratio
−18.2x−12.7x−0.5x
PEG Ratio
−0.650.040.00
Price/Book
17.4x3.2x2.6x
Price / LTM Sales
1,658.6x12.6x3.3x
Upside (Analyst Target)
-12.4%42.9%
Fair Value Upside
Unlock−2.4%6.2%Unlock

Earnings

Latest Release
Apr 24, 2025
EPS / Forecast
-0.09 / --
Revenue / Forecast
-4,060,000.00 / --
EPS Revisions
a
a
Unlock
Last 90 days

3681 Income Statement

FAQ

What Stock Exchange Does SinoMab BioSci Trade On?

SinoMab BioSci is listed and trades on the Hong Kong Stock Exchange stock exchange.

What Is the Stock Symbol for SinoMab BioSci?

The stock symbol for SinoMab BioSci is "3681."

What Is the SinoMab BioSci Market Cap?

As of today, SinoMab BioSci market cap is 3.67B.

What Is SinoMab BioSci's Earnings Per Share (TTM)?

The SinoMab BioSci EPS (TTM) is -0.17.

From a Technical Analysis Perspective, Is 3681 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.

How Many Times Has SinoMab BioSci Stock Split?

SinoMab BioSci has split 0 times.

How Many Employees Does SinoMab BioSci Have?

SinoMab BioSci has 95 employees.

What is the current trading status of SinoMab BioSci (3681)?

As of 11 Aug 2025, SinoMab BioSci (3681) is trading at a price of 3.05, with a previous close of 3.05. The stock has fluctuated within a day range of 2.89 to 3.12, while its 52-week range spans from 0.80 to 3.76.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.